A cohort study investigates a potential correlation between the stresses caused by Mother Nature and mental health.
Over the past few years, wildfires in the United States have grown in prominence—especially on the West Coast in California, and more recently, along the northeastern Texas panhandle and western Oklahoma. These wildfires can break out naturally, but climate change has been a contributing factor to frequency, duration, and intensity of these fires.
They can cause not only structural damage, but can also disrupt ecosystems and cause additional air pollution as a result of the smoke. A dive into the physical health effects that wildfires produce has already been examined before, but the mental health angle, including anxiety disorders, depression, and posttraumatic stress disorder (PTSD), has barely been explored in the context of psychotropic medication prescriptions.
For that reason, the authors of a study published in JAMA Network Open1 sought to explore the association between large wildfire frequency and the rates of prescriptions for psychotropic meds immediately after a fire has started.
With the help of interrupted time-series analysis, the cohort study examined psychotropic medication prescriptions in the six weeks before and after each of the 25 wildfires that occurred in California from 2011-2018. In order to meet the wildfire criteria, over 25,000 acres needed to have burned from one fire. Participants consisted of people living in California metropolitan statistical areas (MSAs) who had psychotropic medications prescriptions. There were entered into the Merative MarketScan Research Database (MarketScan) over the course of those seven years. Statistical analysis was performed for these 25 large wildfires occurring between September 2011 and November 2018.
Other than age (18-44 and 45-64 years of age) and gender (male or female), patients were categorized according to a variety of different psychotropic medication groups, and seven daily time series were created at the MSA level:
In order to gain a better grasp on this association between the mediation use and instances of wildfires, an interrupted time-series (ITS) regression framework was used. MarketScan was able to pull qualities of 7,115,690 people (annual mean [range]: 889,461 [455,705-1,426,928] individuals) who lived residing in MSAs impacted by fires; the mean (range) percentage of enrollees who had at least one outpatient drug claim was 22% (21%-23%) for psychotropic medications, and 12% (11%-13%) for statin meds.
When compared with a pre-fire baseline, the study found a statistically significant increase in prescriptions of antidepressants (rate ratio [RR], 1.04 [95% CI, 1.01-1.07]), anxiolytics (RR, 1.05 [95% CI, 1.02-1.09]), and mood-stabilizing medications (RR, 1.06 [95% CI, 1.01-1.13]) in the fire period. Nonetheless, there were no major correlations reported for antipsychotic, hypnotic, or statin prescriptions.
As a result, the study authors concluded that “…the analysis demonstrated a significant association between psychotropic medication fills and wildfires consistent with previous literature describing mental health risk associated with wildfires, but on a broader spatial and timescale using administrative prescription data. These findings warrant further examination of mental health effects related to wildfires, including exploration of exposure pathways and mechanisms for mental health effects, incident diagnoses compared with exacerbation of preexisting mental health conditions, and identification of mental health needs in communities and populations disproportionately affected by wildfires.
“Further investigation on mental health prescription medications is needed, particularly focusing on populations with limited or no access to mental health services, so that appropriate public health measures can be implemented with an emphasis on addressing medication needs of affected populations.”
Reference
1. Wettstein ZS, Vaidyanathan A. Psychotropic Medication Prescriptions and Large California Wildfires. JAMA Netw Open. 2024;7(2):e2356466. doi:10.1001/jamanetworkopen.2023.56466
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.